Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Registry of Iclusig® (Ponatinib) Used in Clinical Practice for the Treatment of Patients With Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

NCT03678454 is registered in ClinicalTrials.gov with Incyte Biosciences Benelux as lead sponsor.

NCT NCT03678454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03678454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Registry of Iclusig® (Ponatinib) Used in Clinical Practice for the Treatment of Patients With Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Lead sponsor
Incyte Biosciences Benelux
Phase
Observational
Overall status
Completed
Start date
February 3, 2017
Completion date
March 31, 2022
Enrollment
80 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, cml, ph+ all, philadelphia chromosome-positive acute lymphoblastic leukemia